Shavit Capital Fund (I-V)
Shavit Capital Fund
Is a fund aimed to create high returns for investors by buying and investing in equity-related securities mainly in later stage/mezzanine rounds, where plans for an IPO or any other form of exit are reasonably demonstrated, and in IPOs and secondary/PIPE offerings.
The funds' most notable investments (and exits) were in Kamada, Superderivatives, Brainsway, Foamix, Rewalk, Intech Pharma.
Latest News (09/2020): The five funds raised $200M+ are invested in Mapi Pharma, Polus, Gamidacell, BioCancell, AlphaTau, Syqe, Trax, Ayala Pharma and Polypid.
Leon Recanati was a Venture Partner in NGN BioMed II, and worked with NGN Capital on fund raising from investors, and thereafter in identifying and investing in mid/late stage Israeli based healthcare companies.
NGN managed $180M with flexibility to invest in a broad cross section of Healthcare and Biotechnology segments. NGN II was a Venture Capital fund dedicated to Healthcare investing, focusing on ventures with the potential to achieve above average private equity returns with an emphasis on later stage investments. The fund concluded its investment period and is in the final stages of realizing its portfolio.
Rhodium is a private investing firm established by Daniel Recanati in 2006, focusing on high growth cutting-edge opportunities in the fields of Internet, New-media, Mobile and new technologies in general.
Our mission is to identify the most promising entrepreneurs and help them to build thriving companies.
Our focus on diverse innovative technology start-up ventures stems from our passion and experience in the field, which enable us to bring substantial and sustainable value and commitment to entrepreneurs.
Our commitment is to support entrepreneurs and strengthen their ventures with our resources: funding, broad management expertise and an extensive valuable network of business contacts around the globe.
We stand to take an active role in most of our portfolio companies. We strategically invest in a handful of promising companies each year to allow us to be actively involved in creating the optimum environment for them to successfully transform into world class business ventures.
We are dedicated to value creation through each phase of the firm’s life-cycle, from early-stage to market leadership.
Regardless of the size of our initial investment, we like to continue to support our portfolio companies throughout their financing lifecycles.
Our passion is partnering with talented entrepreneurs to turn their ideas into industry-leading companies that will make a difference in our world.